.jetcityimage/iStock Editorial via Getty Images Morgan Stanley has actually opted for Eli Lilly (NYSE: LLY) as its leading biopharma pick for 2025 as well as ranked an additional nine labels in the space as overweight. The financial investment financial institution said in a keep in mind that it continues to believe “diabesity is set to become.